These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 23471820)
1. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820 [TBL] [Abstract][Full Text] [Related]
2. Discovering what makes STAT signaling TYK in T-ALL. Fontan L; Melnick A Cancer Discov; 2013 May; 3(5):494-6. PubMed ID: 23658297 [TBL] [Abstract][Full Text] [Related]
3. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185 [TBL] [Abstract][Full Text] [Related]
4. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473 [TBL] [Abstract][Full Text] [Related]
5. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Prutsch N; Gurnhofer E; Suske T; Liang HC; Schlederer M; Roos S; Wu LC; Simonitsch-Klupp I; Alvarez-Hernandez A; Kornauth C; Leone DA; Svinka J; Eferl R; Limberger T; Aufinger A; Shirsath N; Wolf P; Hielscher T; Sternberg C; Aberger F; Schmoellerl J; Stoiber D; Strobl B; Jäger U; Staber PB; Grebien F; Moriggl R; Müller M; Inghirami GG; Sanda T; Look AT; Turner SD; Kenner L; Merkel O Leukemia; 2019 Mar; 33(3):696-709. PubMed ID: 30131584 [TBL] [Abstract][Full Text] [Related]
6. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603 [TBL] [Abstract][Full Text] [Related]
7. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356 [TBL] [Abstract][Full Text] [Related]
11. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia. Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281 [TBL] [Abstract][Full Text] [Related]
12. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin. Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431 [TBL] [Abstract][Full Text] [Related]
13. Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells. Zgheib A; Pelletier-Bonnier É; Levros LC; Annabi B Cytokine; 2013 Aug; 63(2):187-93. PubMed ID: 23688618 [TBL] [Abstract][Full Text] [Related]
14. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells. Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668 [TBL] [Abstract][Full Text] [Related]